Form 4: Avalo Therapeutics CEO Acquires Performance Stock Units

Avalo Therapeutics CEO Garry Arthur acquired 100,200 performance stock units that will vest in August 2028, following the certification of performance goals.

Summary

• Garry Arthur, CEO and Director of Avalo Therapeutics, Inc., acquired 100,200 performance stock units (PSUs) on May 21, 2026.
• These PSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit upon achievement of certain performance goals.
• The Compensation Committee of Avalo Therapeutics certified the achievement of these performance goals on May 21, 2026.
• The shares subject to these PSUs will fully vest on August 19, 2028, provided Mr. Arthur continues his service with the company until that date.
• Following this transaction, Mr. Arthur beneficially owns 190,314 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard executive compensation event (PSU vesting) rather than significant financial performance or strategic shifts.

Positives

• Certification of performance goals for 100,200 PSUs indicates progress towards company objectives.
• Full vesting of PSUs in August 2028 suggests a long-term commitment from the CEO.
• CEO's continued service until vesting date implies confidence in the company's future.

Negatives

• The acquisition of PSUs is contingent on continued service and achievement of performance goals, with vesting not occurring until August 19, 2028.
• The filing does not provide specific details on the performance goals that were met.

Risks

• Risk of forfeiture of PSUs if the Reporting Person's continued service is not maintained until the vesting date of August 19, 2028.
• The value of the PSUs is subject to the future performance and stock price of Avalo Therapeutics, Inc.

Future Outlook

The performance stock units are set to vest on August 19, 2028, contingent upon the reporting person's continued service. This indicates a forward-looking incentive tied to long-term company performance and executive retention.

Management Comments

• The Compensation Committee of the Issuer certified achievement of such performance goals.
• As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

Industry Context

StockSavvy.ai notes that the use of performance stock units (PSUs) is a common executive compensation tool in the biotechnology and pharmaceutical sectors, aligning management's interests with long-term value creation and achievement of specific milestones.

Stakeholder Impact

• Shareholders: The vesting of PSUs is a standard compensation practice and does not immediately impact share count or value, but it signifies continued executive commitment.
• Employees: The certification of performance goals may indicate positive progress within the company, potentially boosting morale.
• Management: The CEO's PSU award is tied to long-term performance and continued service, aligning his incentives with the company's success.

Next Steps

• Continued service by Garry Arthur until August 19, 2028, for the PSUs to vest.
• Monitoring of Avalo Therapeutics' performance against goals that led to PSU certification.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Form 4, SEC Filing, Stock Options, Performance Stock Units, Executive Compensation, Insider Trading, Beneficial Ownership, Garry Arthur